Novel swine-origin influenza A virus in humans: another pandemic knocking at the door

Influenza A viruses represent a continuous pandemic threat. In April 2009, a novel influenza A virus, the so-called swine-origin influenza A (H1N1) virus (S-OIV), was identified in Mexico. Although S-OIV originates from triple-reassortant swine influenza A (H1) that has been circulating in North American pig herds since the end of the 1990s, S-OIV is readily transmitted between humans but is not epidemic in pigs. After its discovery, S-OIV rapidly spread throughout the world within few weeks. In this review, we sum up the current situation and put it into the context of the current state of knowledge of influenza and influenza pandemics. Some indications suggest that a pandemic may be mild but even “mild” pandemics can result in millions of deaths. However, no reasonable forecasts how this pandemic may develop can be made at this time. Despite stockpiling by many countries and WHO, antiviral drugs will be limited in case of pandemic and resistances may emerge. Effective vaccines are regarded to be crucial for the control of influenza pandemics. However, production capacities are restricted and development/production of a S-OIV vaccine will interfere with manufacturing of seasonal influenza vaccines. The authors are convinced that S-OIV should be taken seriously as pandemic threat and underestimation of the menace by S-OIV to be by far more dangerous than its overestimation.

[1]  E. Gruys,et al.  An overview of swine influenza. , 2006, The Veterinary quarterly.

[2]  R. Brookmeyer,et al.  Incubation periods of acute respiratory viral infections: a systematic review , 2009, The Lancet Infectious Diseases.

[3]  Declan Butler,et al.  Swine flu goes global , 2009, Nature.

[4]  M. Gardam,et al.  Transmission of influenza A in human beings. , 2007, The Lancet. Infectious diseases.

[5]  M. Beck,et al.  Host nutritional status: the neglected virulence factor , 2004, Trends in Microbiology.

[6]  Cécile Viboud,et al.  Epidemiologic characterization of the 1918 influenza pandemic summer wave in Copenhagen: implications for pandemic control strategies. , 2008, The Journal of infectious diseases.

[7]  H. Doerr,et al.  The threat of avian influenza A (H5N1). Part IV: development of vaccines , 2007, Medical Microbiology and Immunology.

[8]  Keiji Fukuda,et al.  Mortality associated with influenza and respiratory syncytial virus in the United States. , 2003, JAMA.

[9]  N. J. White,et al.  Pharmacokinetics of High-Dose Oseltamivir in Healthy Volunteers , 2008, Antimicrobial Agents and Chemotherapy.

[10]  R. Jacobson,et al.  Influenza virus resistance to antiviral agents: a plea for rational use. , 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[11]  Brian Chin,et al.  Estimation of potential global pandemic influenza mortality on the basis of vital registry data from the 1918–20 pandemic: a quantitative analysis , 2006, The Lancet.

[12]  N. Ferguson,et al.  Time lines of infection and disease in human influenza: a review of volunteer challenge studies. , 2008, American journal of epidemiology.

[13]  Rong Wang,et al.  Influenza Virus PB1-F2 Protein Induces Cell Death through Mitochondrial ANT3 and VDAC1 , 2005, PLoS pathogens.

[14]  R. Davey,et al.  Pharmacokinetics and Tolerability of Oseltamivir Combined with Probenecid , 2008, Antimicrobial Agents and Chemotherapy.

[15]  E. Lyons,et al.  Pandemic Potential of a Strain of Influenza A (H1N1): Early Findings , 2009, Science.

[16]  J. Taubenberger,et al.  1918 Influenza: the Mother of All Pandemics , 2006, Emerging infectious diseases.

[17]  N. Khardori,et al.  Triple-Reassortant Swine Influenza A (H1) in Humans in the United States, 2005–2009 , 2009 .

[18]  Michael Gardam,et al.  Transmission of influenza A in human beings. , 2007, The Lancet. Infectious diseases.

[19]  M. Vey,et al.  Influenza virus hemagglutinin with multibasic cleavage site is activated by furin, a subtilisin‐like endoprotease. , 1992, The EMBO journal.

[20]  Robert T. Chen,et al.  Anti-ganglioside antibody induction by swine (A/NJ/1976/H1N1) and other influenza vaccines: insights into vaccine-associated Guillain-Barré syndrome. , 2008, The Journal of infectious diseases.

[21]  A. Moscona,et al.  Global transmission of oseltamivir-resistant influenza. , 2009, The New England journal of medicine.

[22]  L. Simonsen,et al.  The impact of influenza epidemics on mortality: introducing a severity index. , 1997, American journal of public health.

[23]  David E. Swayne,et al.  Characterization of the Reconstructed 1918 Spanish Influenza Pandemic Virus , 2005, Science.

[24]  H. Doerr,et al.  The threat of avian influenza a (H5N1): part II: Clues to pathogenicity and pathology , 2007, Medical Microbiology and Immunology.

[25]  H. Doerr,et al.  The threat of avian influenza A (H5N1). Part III: antiviral therapy , 2007, Medical Microbiology and Immunology.

[26]  D. Suarez,et al.  The Effect of Various Disinfectants on Detection of Avian Influenza Virus by Real Time RT-PCR , 2003, Avian diseases.

[27]  E. Gruys,et al.  An overview of swine influenza , 2006, The Veterinary quarterly.

[28]  H. Doerr,et al.  Laboratory diagnosis of influenza – virology or serology? , 2002, Medical Microbiology and Immunology.

[29]  S. Salzberg,et al.  Large-scale sequencing of human influenza reveals the dynamic nature of viral genome evolution , 2005, Nature.

[30]  N. Khardori Emergence of a Novel Swine-Origin Influenza A (H1N1) Virus in Humans , 2009 .

[31]  M. Kurokawa,et al.  Early augmentation of interleukin (IL)-12 level in the airway of mice administered orally with clarithromycin or intranasally with IL-12 results in alleviation of influenza infection. , 2001, The Journal of pharmacology and experimental therapeutics.

[32]  T. Hussell,et al.  Bacterial complications during pandemic influenza infection. , 2009, Future microbiology.

[33]  Amanda Balish,et al.  Triple-reassortant swine influenza A (H1) in humans in the United States, 2005-2009. , 2009, The New England journal of medicine.

[34]  R. Webster,et al.  Animal influenza epidemiology. , 2008, Vaccine.

[35]  J. Marks,et al.  Guillain-Barré syndrome in recipients of A/New Jersey influenza vaccine. , 1980, JAMA.

[36]  Raymond Tellier,et al.  Review of Aerosol Transmission of Influenza A Virus , 2006, Emerging infectious diseases.

[37]  J. R. Coleman The PB1-F2 protein of Influenza A virus: increasing pathogenicity by disrupting alveolar macrophages , 2007, Virology Journal.

[38]  Anthony S Fauci,et al.  Predominant role of bacterial pneumonia as a cause of death in pandemic influenza: implications for pandemic influenza preparedness. , 2008, The Journal of infectious diseases.

[39]  Yoshihiro Kawaoka,et al.  Molecular Basis for High Virulence of Hong Kong H5N1 Influenza A Viruses , 2001, Science.

[40]  R. Webster,et al.  The Influenza Virus Enigma , 2009, Cell.

[41]  Mark A. Miller,et al.  Synchrony, Waves, and Spatial Hierarchies in the Spread of Influenza , 2006, Science.

[42]  R. Webster,et al.  Molecular Basis of Replication of Duck H5N1 Influenza Viruses in a Mammalian Mouse Model , 2005, Journal of Virology.

[43]  H. Klenk,et al.  The viral polymerase mediates adaptation of an avian influenza virus to a mammalian host. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[44]  H. Doerr,et al.  Of chickens and men: avian influenza in humans. , 2009, Current molecular medicine.

[45]  Yoshihiro Kawaoka,et al.  Influenza: lessons from past pandemics, warnings from current incidents , 2005, Nature Reviews Microbiology.

[46]  Gabriele Neumann,et al.  Host Range Restriction and Pathogenicity in the Context of Influenza Pandemic , 2006, Emerging infectious diseases.

[47]  E. Thacker,et al.  Swine influenza virus: zoonotic potential and vaccination strategies for the control of avian and swine influenzas. , 2008, The Journal of infectious diseases.

[48]  B. Obama,et al.  Reflections on the 1976 Swine Flu Vaccination Program , 2006, Emerging infectious diseases.

[49]  Gregory C Gray,et al.  Cases of swine influenza in humans: a review of the literature. , 2007, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[50]  J A Bryan,et al.  Guillain-Barre syndrome following vaccination in the National Influenza Immunization Program, United States, 1976--1977. , 1979, American journal of epidemiology.

[51]  Update : Drug Susceptibility of Swine-Origin Influenza A ( H 1 N 1 ) Viruses , 2022 .

[52]  D. Miyamoto,et al.  Clarithromycin inhibits progeny virus production from human influenza virus-infected host cells. , 2008, Biological & pharmaceutical bulletin.

[53]  H. Doerr,et al.  The threat of avian influenza A (H5N1). Part I: epidemiologic concerns and virulence determinants , 2007, Medical Microbiology and Immunology.